Previous Section
New Developments in Ductal Carcinoma in Situ
Research is ongoing to better define the role of adjuvant hormonal therapy in the management of women with ductal carcinoma in Situ (DCIS).
Research is ongoing to better define the role of radiation therapy in the management of women with DCIS.
Research is ongoing to more accurately identify women with DCIS who are at high risk for recurrence of breast cancer (invasive or in situ).
Newer imaging techniques are being investigated to improve the accuracy of early breast cancer screening and detection.
The role of oral contraceptives as a risk factor for DCIS is being investigated.
The use of biological markers that can potentially more accurately predict the risk of recurrence in patients with DCIS following surgery is being investigated.
The risk of recurrence following treatment of DCIS with skin-sparing mastectomy and immediate breast reconstruction is under investigation.
The potential role of newer selective estrogen receptor modulators (SERMs) as adjuvant therapy in women with estrogen-receptor positive DCIS is being investigated.
The role of cyclo-oxygenase 2 (COX-2) inhibitors in the treatment of DCIS is under investigation.
Mammary ductoscopy , a new imaging technique that allows doctors to better visualize the ductal system of the breasts, is emerging as a potentially important tool in guiding breast-conserving surgery for DCIS.
Information regarding ongoing clinical studies in your area can be obtained at the Clinical Trials Listing Service at http://www.centerwatch.com
